Evidence map›Paper›PMID 32938582›Full record

ArticleBMJ open gastroenterology2020

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.

Matthew J Brookes, John Waller, Joseph C Cappelleri, Irene Modesto, Marco D DiBonaventura, Natalie Bohm, Ruth Mokgokong, Olivia Massey, Robert Wood, Danielle Bargo

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMJ open gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Matthew J BrookesGastroenterology Department, Royal Wolverhampton NHS Trust, Wolverhampton, UK.ORCID 0000-0002-8782-0292
John WallerAdelphi Real World, Bollington, UK.
Joseph C CappelleriBiostatistics, Pfizer Inc, Groton, Connecticut, USA.
Irene ModestoInflammation & Immunology, Pfizer Inc, New York, New York, USA.
Marco D DiBonaventuraPatient Health Impact, Pfizer Inc, New York, New York, USA Marco.DiBonaventura@pfizer.com.
Natalie BohmPfizer Inc, Tadworth, UK.
Ruth MokgokongPfizer Inc, Tadworth, UK.
Olivia MasseyAdelphi Real World, Bollington, UK.
Robert WoodAdelphi Real World, Bollington, UK.
Danielle BargoPatient Health Impact, Pfizer Inc, New York, New York, USA.
Pfizer (United States) · USAdelphi Group (United Kingdom) · GBPfizer (United Kingdom) · GBUniversity of Wolverhampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUlcerative colitis (UC) is a lifelong, relapsing-remitting disease. Patients non-responsive to pharmacological treatment may require a colectomy. We estimated pre-colectomy and post-colectomy healthcare resource utilisation (HCRU) and costs in England. DESIGN/

methodA retrospective, longitudinal cohort study indexing adult patients with UC undergoing colectomy (2009-2015), using linked Clinical Practice Research Datalink/Hospital Episode Statistics data, was conducted. HCRU, healthcare costs and pharmacological treatments were evaluated during 12 months prior to and including colectomy (baseline) and 24 months post-colectomy (follow-up; F-U), comparing baseline/F-U, emergency/elective colectomy and subtotal/full colectomy using descriptive statistics and paired/unpaired tests.

results249 patients from 26 165 identified were analysed including 145 (58%) elective and 184 (74%) full colectomies. Number/cost of general practitioner consultations increased post-colectomy (p<0.001), and then decreased at 13-24 months (p<0.05). From baseline to F-U, the number of outpatient visits, number/cost of hospitalisations and total direct healthcare costs decreased (all p<0.01). Postoperative HCRU was similar between elective and emergency colectomies, except for the costs of colectomy-related hospitalisations and medication, which were lower in the elective group (p<0.05). Postoperative costs were higher for subtotal versus full colectomies (p<0.001). At 1-12 month F-U, 30%, 19% and 5% of patients received aminosalicylates, steroids and immunosuppressants, respectively.

conclusionHCRU/costs increased for primary care in the first year post-colectomy but decreased for secondary care, and varied according to the colectomy type. Ongoing and potentially unnecessary pharmacological therapy was seen in up to 30% of patients. These findings can inform patients and decision-makers of potential benefits and burdens of colectomy in UC.

Indexed as

AdultAgedClinical Decision-MakingCohort StudiesColectomyColitis, UlcerativeElective Surgical ProceduresEmergenciesEnglandFemaleFollow-Up StudiesHealth Care CostsHealth ResourcesHospitalizationHumansLongitudinal Studiescolorectal surgeryhealth economicsulcerative colitis

Identifiers

PMID32938582
PMCPMC7497134
OpenAlexW3087156127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.